All Posts

By Steve Wolk, Ph.D., founder and chief consultant, Sinawali Biotechnology Solutions The 2026 TIDES conference was held in Boston, May 11-15. As always, it was a great opportunity to reconnect with old colleagues, establish new relationships, and of course hear the newest updates across the broad spectrum of oligonucleotide and peptide technologies and the latest clinical advances. As a high-level overview, it seems reasonable to organize the highlights into four main buc

Steve Wolk, September 1, 2025 There are two key chains of events that can impact therapeutic potency. A break in the chain at any stage can cause reduction or catastrophic failure of therapeutic potency. The first is the manufacturing chain of events, or the cold chain path, which may include any or all of the following steps: Manufacturer --> Distributor --> Wholesaler --> Pharmacist --> Patient Factors affecting potency include: Temperature Light exposure Air (oxidation) e

Steve Wolk, 14JAN2026 Targeted Delivery. In simple terms, targeted delivery refers to getting a drug to, and only to, the places in the body where it can provide therapeutic benefit. In the gene editing world, the various constructs that have been developed for CRISPR gene editing, such as nuclease editing, base editing, and prime editing, work extremely well for editing cells in a dish. However, we are still not very good at delivering these gene editing machines in a